Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand

Pathology

Volumn 41, Issue 6, 2009, Pages 582-584

  Pandey, Sushil ^a   Newton, Sandie ^a   Upton, Arlo ^a,b   Roberts, Sally ^a   Drinkovi, Dragana ^a,c  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b WHANGAREI HOSPITAL   (New Zealand)

^c NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

Genotypic analysis; Mycobacterium tuberculosis; Pyrazinamide resistance

Indexed keywords

AMINO ACID; PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; GENE MUTATION; GENE SEQUENCE; GENOTYPE; MYCOBACTERIUM TUBERCULOSIS; NEW ZEALAND; NONHUMAN; PHENOTYPE; PNCA GENE;

EID: 70350648031     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020903071587     Document Type: Article

References (27)

1. World Health Organization. Report of the Tuberculosis Epidemic. Geneva: World Health Organization, 1996.
2. Institute of Environmental Science and Research Limited. Notifiable and Other Diseases in New Zealand: Annual Report 2006. Wellington: Institute of Environmental Science and Research Limited, 2007.
3. Heffernan H. Antituberculosis Drug Resistance in New Zealand, 2006. Wellington: Institute of Environmental Science and Research Limited, 2007.
4. Mackaness GB. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc 1956; 74: 718-728
5. Butler WR, Kilburn JO. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother 1983; 24: 600-601
6. McClatchy JK, Tsang AY, Cernich MS. Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother 1981; 20: 556-557
7. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70: 748-754
8. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543
9. Wayne LG. Simple pyrazinamidase and urease tests for routine Identification of mycobacteria. Am Rev Respir Dis 1974; 109: 147-151
10. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-667
11. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic ampli.cation of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491
12. Scorpio A, Collins D, Whipple D, et al. Rapid Differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 1997; 35: 106-110
13. Sreevatsan S, Pan X, Zhang Y, et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: 636-640
14. Huang TS, Lee SS, Tu HZ, et al. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother 2003; 47: 3672-3673
15. Jureen P, Werngren J, Toro JC, et al. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 1852-1854
16. Cheng SJ, Thibert L, Sanchez T, et al. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000; 44: 528-532
17. Hirano K, Takahashi M, Kazumi Y, et al. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1997; 78: 117-122
18. Lemaitre N, Sougako. W, Truffot-Pernot C, et al. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and Identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 1999; 43: 1761-1763
19. Marttila HJ, Marjamaki M, Vyshnevskaya E, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 1999; 43: 1764-1766
20. Mestdagh M, Fonteyne PA, Realini L, et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 2317-2319
21. Morlock GP, Crawford JT, Butler WR, et al. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2291-2295
22. Escalante P, Ramaswamy S, Sanabria H, et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis 1998; 79: 111-118 (Pubitemid 29078280)
23. Park SK, Lee JY, Chang CL, et al. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis 2001; 1: 4.
24. Hou L, Osei-Hyiaman D, Zhang Z, et al.Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 2000; 124: 227-232
25. Barco P, Cardoso RF, Hirata RD, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 2006; 58: 930-935
26. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225
27. Raynaud C, Laneelle MA, Senaratne RH, et al. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999; 145: 1359-1367